Unlike conventional pharmaceutical manufacturing, cell-based production often works with living cells whose characteristics can change in response to their environment. This makes process control, material handling, testing, and documentation important parts of the overall manufacturing approach.

The field developed alongside advances in cell biology, tissue engineering, biotechnology, and pharmaceutical manufacturing. Early cell-based processes often involved substantial manual handling, while newer approaches increasingly use closed equipment, digital monitoring, and automated workflows. Today, cell therapy manufacturing may support both patient-specific approaches, in which cells are processed for an individual patient, and donor-derived approaches, in which cells from a donor are prepared for use across multiple treatment units.

A typical cell therapy manufacturing process can include several connected stages. Depending on the therapy, these may involve receiving and identifying starting material, cell isolation, activation or modification, cell expansion, harvesting, formulation, quality testing, storage, and final preparation.

Understanding the Manufacturing Environment

Cell therapy manufacturing facilities are designed around controlled processing areas, equipment, material movement, environmental monitoring, and quality systems. The exact layout depends on the type of therapy and whether production is intended for clinical development or commercial manufacturing.

Cell therapy manufacturing equipment can include bioreactors, cell washers, centrifugation systems, incubators, controlled-rate freezers, filling equipment, analytical instruments, and closed processing devices. Cell therapy processing equipment is selected according to the characteristics of the cells and the steps required by the manufacturing process.

From Manual Processing to Integrated Systems

Traditional workflows can involve multiple manual transfers between separate pieces of equipment. Modern cell therapy production systems increasingly connect several steps through closed or semi-closed processing methods.

Cell therapy manufacturing systems may combine processing equipment, software, sensors, electronic records, and quality controls. Some advanced cell therapy production systems are designed as modular platforms, while others connect multiple stages into a broader workflow.

Importance

Cell therapy manufacturing matters because manufacturing quality can affect the identity, purity, viability, potency, and consistency of a cell-based product. These characteristics are influenced by the starting material, processing conditions, equipment, materials, storage conditions, and testing methods.

The subject affects researchers, manufacturing personnel, healthcare organizations, regulators, and patients who may eventually receive products developed through these processes. Clinical cell therapy manufacturing also has to accommodate the practical requirements of clinical studies, where production may involve relatively small numbers of patient-specific batches.

Managing Living Biological Material

Living cells are sensitive to changes in temperature, nutrients, handling conditions, and processing environments. Small differences between process steps can therefore influence the resulting cell population.

Cell therapy processing systems are designed to provide controlled environments for these activities. Depending on the process, monitoring may include cell concentration, viability, environmental conditions, processing time, and other quality-related measurements.

Supporting Quality and Traceability

GMP cell therapy manufacturing involves documented procedures, controlled materials, equipment qualification, environmental controls, testing, and records that support product quality. Good manufacturing practice requirements vary according to jurisdiction and product type, so manufacturers must follow the applicable regulatory framework.

Traceability is another important consideration. Patient-specific materials may need to remain associated with the correct identity throughout processing. Electronic records, barcode systems, controlled labeling, and documented material movement can help maintain this connection.

Autologous and Allogeneic Approaches

Cell therapy production can generally be divided into two broad models. Autologous approaches use cells obtained from the individual who will receive the resulting product, while allogeneic approaches use cells from a donor.

These models create different manufacturing requirements. Autologous production emphasizes identity tracking and coordination, while allogeneic production places additional attention on donor material, batch consistency, scalability, and storage.

Recent Updates

From 2024 through 2026, cell therapy manufacturing has increasingly focused on process standardization, automation, closed processing, digital records, and approaches that can support manufacturing at larger scales. Regulatory agencies have also continued updating guidance related to chemistry, manufacturing, and controls.

The U.S. Food and Drug Administration published guidance in 2024 addressing the use of human- and animal-derived materials in manufacturing cell and gene therapy products. The guidance discussed considerations including material identity, consistency between lots, and the potential for adventitious agents.

In 2026, the FDA described a more flexible approach to certain chemistry, manufacturing, and controls requirements for cell and gene therapies. The agency noted that validation and comparability approaches can be considered through a product lifecycle and according to the characteristics of individual products and processes.

Automation and Closed Processing

Automated cell therapy manufacturing systems are receiving increased attention because many existing workflows involve repeated manual operations. Closed systems can reduce the number of open handling steps and can connect multiple processing stages.

Current industry discussions also identify challenges involving small-volume processing, scalability, flexibility, usability, and compliance with GMP requirements. Automation is therefore developing alongside efforts to understand where automated equipment fits within different manufacturing workflows.

Digital Manufacturing and Process Monitoring

Cell therapy manufacturing technology is also becoming more connected. Electronic batch records, equipment monitoring, data collection, and process analytics can help organize information from multiple manufacturing steps.

This development supports greater use of data throughout the manufacturing lifecycle. However, digital integration requires appropriate data controls, system validation, cybersecurity measures, and procedures for handling deviations or equipment problems.

Regulatory Development

Regulatory attention continues to address manufacturing changes, process validation, potency, materials, and long-term product monitoring. FDA guidance indicates that there is no universally fixed minimum number of process performance qualification batches for human cell and gene therapy products; the appropriate approach can depend on process complexity, controls, and available process understanding.

FDA also issued additional cell and gene therapy guidance during 2026, including guidance covering development questions and chemistry, manufacturing, and controls considerations.

Tools and Resources

Cell therapy manufacturing requires a combination of physical equipment, analytical tools, software, documentation, and quality systems. The specific combination depends on the product, process stage, regulatory environment, and manufacturing scale.

Manufacturing Equipment

Cell therapy production equipment may include:

• Cell expansion and culture systems for controlled cell growth.
• Centrifugation and washing equipment for cell separation and preparation.
• Closed processing systems for reducing open handling steps.
• Cryogenic and controlled-rate freezing equipment for cell preservation.
• Filling systems for preparing defined product quantities.
• Analytical instruments for assessing relevant product characteristics.

Cell therapy bioprocessing equipment can also include sensors and monitoring systems that record process conditions. These tools may be integrated into broader cell therapy manufacturing systems.

Documentation and Process Resources

Process maps, batch records, equipment logs, material specifications, and standard operating procedures are important resources in a controlled manufacturing environment. These documents describe how individual steps should be performed and recorded.

Regulatory websites are another important resource. The FDA's cellular and gene therapy guidance library provides information covering manufacturing, development, quality considerations, and related regulatory topics.

Automation and Data Platforms

Advanced cell therapy manufacturing may use software to coordinate equipment, track materials, collect process information, and manage electronic records. Process monitoring platforms can help organize information generated throughout production.

Complete cell therapy manufacturing systems may combine several of these functions, although the meaning of "complete" varies by manufacturer and process. Modular approaches can instead allow individual technologies to be connected as the manufacturing workflow develops.

FAQs

What is cell therapy manufacturing?

Cell therapy manufacturing involves processing living cells through controlled steps to create a cell-based therapeutic product. Activities can include cell preparation, modification, expansion, harvesting, formulation, testing, and storage.

What equipment is used in cell therapy manufacturing?

Cell therapy manufacturing equipment can include bioreactors, centrifuges, cell washers, incubators, freezing systems, filling equipment, analytical instruments, and closed processing platforms. The equipment used depends on the specific manufacturing process.

How does automated cell therapy manufacturing work?

Automated cell therapy manufacturing uses equipment, software, sensors, and predefined process instructions to perform or coordinate selected manufacturing steps. Automation can range from individual processing steps to connected automated cell therapy manufacturing systems.

What is GMP cell therapy manufacturing?

GMP cell therapy manufacturing refers to production conducted under applicable good manufacturing practice requirements. These requirements address areas such as controlled processes, documentation, equipment, materials, testing, and quality oversight.

What is the difference between clinical and commercial cell therapy manufacturing?

Clinical cell therapy manufacturing supports products used during clinical development, while commercial cell therapy manufacturing supports products intended for authorized broader distribution. Requirements and manufacturing strategies can evolve as a product progresses through development and regulatory review.

Conclusion

Cell therapy manufacturing combines cell biology with controlled pharmaceutical and bioprocessing methods. Modern approaches increasingly use closed equipment, automation, digital records, and connected cell therapy production systems while maintaining attention to quality and traceability. Recent regulatory developments have also emphasized lifecycle-based approaches to manufacturing controls and validation. The field continues to develop around the practical challenges of processing living cells consistently across clinical and commercial environments.